Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout
- 1 January 2013
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 18 (1-2) , 11-24
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesotheliomaBritish Journal of Pharmacology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsCancer Research, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic AgentsCancer Research, 2011
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197Journal of Biological Chemistry, 2011
- MET as a target for treatment of chest tumorsLung Cancer, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitorsCritical Reviews in Oncology/Hematology, 2007